Pharmaceuticals
turnover in the year was £17,554 million, up 2% AER, but flat
at CER. HIV sales were up 3% AER, 1% CER, to £4,854 million,
with growth in Juluca and
Dovato partly offset by
declines in Triumeq and
Tivicay. Respiratory sales
were up 18% AER, 15% CER, to £3,081 million, on growth of
Trelegy Ellipta and
Nucala. Sales of
Established Pharmaceuticals were £8,776 million, down 7% AER,
8% CER, including the impact of loss of exclusivity of Advair.
In the
US, sales declined 1% AER, 4% CER. Continued growth of Nucala, Trelegy Ellipta and Benlysta was more than offset by the
decline in Established Products including the loss of exclusivity
of Advair. Excluding
Advair and Relvar/Breo Ellipta, which were
impacted by genericisation of the ICS/LABA market, growth was 13%
AER, 9% CER. In Europe, sales grew 1% AER, 2% CER, with strong
growth in Respiratory partly offset by a decline in Established
Pharmaceuticals. International grew 5% AER, 4% CER, with growth in
all therapy areas.
Respiratory
Total
Respiratory sales were up 18% AER, 15% CER, with strong growth in
all regions. Ellipta
product sales grew 13% AER, 10% CER, with Europe up 26% AER, 27%
CER and International up 29% AER, 27% CER on Trelegy and Relvar/Breo growth. Nucala was up 36% AER, 37% CER in
Europe and 56% AER, 50% CER in International. In the US,
Trelegy Ellipta and Nucala growth offset the decline in
Relvar/Breo Ellipta on post generic ICS/LABA price
pressure.
Sales
of Nucala were £768
million in the year and grew 36% AER, 33% CER, with US sales of
£453 million up 33% AER, 28% CER, including the impact of the
new at-home use application.
Sales
of Ellipta products were up
13% AER, 10% CER to £2,313 million driven by growth in Europe
and International regions. In the US, sales grew 4% AER, but were
flat at CER, reflecting continued competitive pricing pressures for
ICS/LABAs, post generic Advair. In Europe, sales grew 26% AER,
27% CER, and in International by 29% AER, 27% CER. Sales of
Trelegy Ellipta contributed
£518 million globally in the year, driven by an increase in US
market share.
Relvar/Breo Ellipta sales were down 11% AER, 13% CER, driven
by the US, where Relvar/Breo Ellipta declined 34% AER, 37% CER as a
result of competitive pricing pressures and the impact of generic
Advair on the US ICS/LABA
market. In Europe and International, Relvar/Breo Ellipta continued to grow, up 11% AER,
12% CER in Europe, and 21% AER, 19% CER in
International.
HIV
HIV
sales grew 3% AER, 1% CER to £4,854 million in the year. The
dolutegravir franchise grew 5% AER, 2% CER, delivering sales of
£4,633 million. The remaining portfolio, £221 million and
5% of total HIV sales, declined 27% AER, 27% CER and reduced the
overall HIV growth by two percentage points at AER and one
percentage point at CER.
Sales
of dolutegravir products were £4,633 million, with
Triumeq and Tivicay delivering sales of £2,549
million and £1,662 million, respectively. The two-drug
regimens, Juluca and
Dovato, delivered sales of
£422 million in the year with combined growth more than
offsetting the decline in the three-drug regimen, Triumeq, as the business transitions to
the new portfolio.
In the
US, following the launch of Dovato in April 2019, combined sales of
the two-drug regimens were £350 million. Total dolutegravir
sales grew 4% AER but were flat at CER, reflecting a year-on-year
share decline as the business transitions to the new two-drug
portfolio, offset by a net price benefit. In Europe, total
dolutegravir sales were flat at AER and flat at CER, with strong
growth in market share offsetting price erosion and higher clawback
payments. Dovato and
Juluca reported combined
sales of £65 million. International grew strongly with total
dolutegravir sales growth of 22% AER, 22% CER, driven by
Tivicay and Triumeq.
Oncology
Sales
of Zejula, were £229
million in the period from the date of acquisition, comprising
£134 million in the US and £95 million in
Europe.
Immuno-inflammation
Sales
of Benlysta in the year
were up 30% AER, 25% CER to £613 million, including sales of
the sub-cutaneous formulation of £268 million. In the US,
Benlysta grew 27% AER, 23%
CER to £535 million.
Established
Pharmaceuticals
Sales
of Established Pharmaceuticals in the year were £8,776
million, down 7% AER, 8% CER.
Established
Respiratory products declined 10% AER, 11% CER to £3,900
million, with the decline in Advair/Seretide partly offset by higher
sales of Ventolin, Flovent
and allergy
products. In the US, a
generic version of Advair
was launched in February, resulting in a 54% AER, 56% CER decline
in the year. In Europe, Seretide sales were down 16% AER, 16%
CER to £502 million, reflecting continued competition from
generic products and the transition of the Respiratory portfolio to
newer products. In International, sales of Seretide were flat at AER but down 1%
CER. Globally, Ventolin
grew by 27% AER, 25% CER, driven by the strong uptake of an
authorised generic version in the US.
The
remainder of the Established Pharmaceuticals portfolio declined 5%
AER, 6% CER to £4,876 million, including Lamictal down 8% AER, 10% CER to
£566 million on generic competition and lower sales of
Viread in International.
These declines were partly offset by Augmentin, up 6% AER, 6% CER to
£602 million in the year, driven by strong growth in
International.
|